[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608658":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":34,"responsibleParty":81,"collaborators":11,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":11,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":11,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"KarXT","EXPERIMENTAL",null,[13],"Drug: Xanomeline\u002F Trospium Chloride",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Xanomeline\u002F Trospium Chloride","Specified dose on specified days",[9],[21,9],"BMS-986510",[23],{"name":24,"affiliation":24,"role":25},"Bristol-Myers Squibb","STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":33,"role":29,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain the NCT# and Site #.",[35,53,67],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Anaheim Clinical Trials","RECRUITING","Anaheim","California","92801","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.9145,33.83529,{"lat":47,"lon":46},[50],{"name":51,"role":29,"phone":52,"phoneExt":11,"email":11},"Peter Winkle, Site 0003","949-295-7809",{"facility":54,"status":37,"city":55,"state":56,"zip":57,"country":41,"countryCode":42,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"ICON - Lenexa","Lenexa","Kansas","66219-9746",{"type":44,"coordinates":59},[60,61],-94.73357,38.95362,{"lat":61,"lon":60},[64],{"name":65,"role":29,"phone":66,"phoneExt":11,"email":11},"Patrick Yao, Site 0002","913-410-2674",{"facility":68,"status":37,"city":69,"state":70,"zip":71,"country":41,"countryCode":42,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"ICON Development Solutions","San Antonio","Texas","78209",{"type":44,"coordinates":73},[74,75],-98.49363,29.42412,{"lat":75,"lon":74},[78],{"name":79,"role":29,"phone":80,"phoneExt":11,"email":11},"Cassandra Key, Site 0001","210-283-4552",{"type":82,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100608658","phase-1-a-study-to-evaluate-the-effects-of-cyp2d6-phenotypes-on-the-pharmacokinetics-of-xanomeline-following-karxt-administration-in-healthy-adult-participants-100608658",false,"NCT07204418","A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants","A Phase 1, 4-part, Open-label Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants","Inclusion Criteria:\n\n* Participant must be healthy male and female (INOCBP) participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs (VS), and clinical laboratory determinations.\n* Participant must be a normal\u002Fextensive, intermediate, poor, or ultrarapid CYP2D6 metabolizer.\n* Participant must have body mass index (BMI) of 18.0 to 32.0 kg\u002Fm2, inclusive.\n\nExclusion Criteria:\n\n* Participants must not have evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population reference ranges.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","65 Years",{"count":95,"type":96},56,"ESTIMATED","INTERVENTIONAL",[99],"PHASE1","The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal\u002Fextensive, intermediate, poor, and ultrarapid metabolizers.",[102],"Healthy Volunteers",[104,105,21,9,106,107],"Healthy volunteer","Pharmacokinetics","Cobenfy","CYP2D6","2026-02-17",{"date":110,"type":111},"2026-02-19","ACTUAL",{"date":113,"type":111},"2025-10-13",{"date":115,"type":96},"2026-12-03",{"name":5,"class":6},3]